Author

David C. Dalgarno

Observed names: D C Dalgarno, D Dalgarno, D. C. DALGARNO, D. C. Dalgarno, D. Dalgarno, D.C Dalgarno, D.C. Dalgarno, DAVID C. DALGARNO, DC Dalgarno, Dalgarno, David C., David C Dalgarno, David C. DALGARNO, David Dalgarno

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Howard Hughes Medical Institute, Oregon Health & Science University, University of Washington, Portland VA Medical Center, University of Rochester Medicine, Helmholtz Munich, Yale University, University of Oxford, Fred Hutch Cancer Center, Brooke, Cambridge Intellectual Property (United Kingdom), Innovative Technology and Science (United Kingdom), ARIAD Pharmaceuticals (United States), Brooks Sports, Inc. (United States), University of Rochester, Bloomfield College, University of Birmingham, Ludwig-Maximilians-Universität München

ORCID: 0009-0003-1081-1608

Observed ORCID: 0009-0003-1081-1608

OpenAlex ID: A5008040654

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

2009 · Thomas O'Hare, William C. Shakespeare, et al. · Cancer Cell · 1,293

PDF

Structural basis for the binding of proline-rich peptides to SH3 domains

1994 · Hongtao Yu, James K. Chen, et al. · Cell · 1,009

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

2016 · Wei-Sheng Huang, Shuangying Liu, et al. · Journal of Medicinal Chemistry · 428

Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

2010 · Wei-Sheng Huang, Chester A. Metcalf, et al. · Journal of Medicinal Chemistry · 381

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

2016 · Sen Zhang, Rana Anjum, et al. · Clinical Cancer Research · 337

PDF

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

2010 · Tianjun Zhou, Lois Commodore, et al. · Chemical Biology & Drug Design · 295

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

2004 · Thomas O'Hare, Roy Pollock, et al. · Blood · 201

PDF

High-throughput prediction of protein conformational distributions with subsampled AlphaFold2

2024 · Gabriel Monteiro da Silva, Jennifer Y. Cui, et al. · Nature Communications · 197

PDF

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

2021 · Francois Gonzalvez, Sylvie Vincent, et al. · Cancer Discovery · 193

SH3 domains and drug design: Ligands, structure, and biological function

1997 · D. C. Dalgarno, M. C. Botfield, et al. · Biopolymers · 166

Structural information from NMR secondary chemical shifts of peptide α C-H protons in proteins

1983 · D. C. Dalgarno, B. A. Levine, et al. · Bioscience Reports · 138

Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis Screen

2011 · Sen Zhang, Frank Wang, et al. · Chemical Biology & Drug Design · 133

PDF

Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity

2000 · William Shakespeare, Michael Yang, et al. · Proceedings of the National Academy of Sciences · 132

Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers

2001 · John D. Iuliucci, Stuart D. Oliver, et al. · The Journal of Clinical Pharmacology · 131

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance

2006 · Mohammad Azam, Valentina Nardi, et al. · Proceedings of the National Academy of Sciences · 107

1H‐NMR studies of calmodulin

1984 · Rachel E. KLEVIT, David C. DALGARNO, et al. · European Journal of Biochemistry · 103

Crystal Structure of the T315I Mutant of Abl Kinase

2007 · Tianjun Zhou, Lois Parillon, et al. · Chemical Biology & Drug Design · 102

Proton Nuclear‐Magnetic‐Resonance Spectroscopy of Myosin Subfragment 1 Isoenzymes

1981 · H. Paul PRINCE, Hylary R. TRAYER, et al. · European Journal of Biochemistry · 98

PDF

1H NMR studies of calmodulin

1984 · David C. DALGARNO, Rachel E. KLEVIT, et al. · European Journal of Biochemistry · 93

PDF

Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma

2006 · Liz Y. Han, Charles N. Landen, et al. · Cancer Research · 92

PDF

Investigating Protein−Ligand Interactions with a Mutant FKBP Possessing a Designed Specificity Pocket

2000 · Wu Yang, Leonard W. Rozamus, et al. · Journal of Medicinal Chemistry · 91

Fragment Growing and Linking Lead to Novel Nanomolar Lactate Dehydrogenase Inhibitors

2013 · Anna Kohlmann, Stephan G. Zech, et al. · Journal of Medicinal Chemistry · 87

Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine‐based Compounds

2005 · David Dalgarno, Thilo Stehle, et al. · Chemical Biology & Drug Design · 86

PDF

The carboxyl-terminal region of human interferon γ is important for biological activity: mutagenic and NMR analysis

1991 · Daniel Lundell, Charles Lunn, et al. · Protein Engineering Design and Selection · 68

Characterization of the actin-binding site on the alkali light chain of myosin

1985 · Gillian D. Henry, Monica A. Winstanley, et al. · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · 65

Works count: 130

Citation count: 7,886

H-index: 41

I10-index: 81